BioCentury
ARTICLE | Clinical News

TB Patch: Phase II data

October 2, 2006 7:00 AM UTC

In a Phase II trial in 96 patients, the TB Patch detected infection with 65% sensitivity and 96% specificity. Sequella has worldwide rights to the patch excluding Japan, where Japan BCG Laboratory has...